ArticleScientific reports2025
Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Antibiotic-induced cellular enlargement drives phage synergy and resensitizes carbapenem-resistantMicrobiology spectrum · 2026Article
- Review
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Using the Damage Response Framework as a Lens to Discuss Acinetobacter baumannii Host-Pathogen Interactions: A Narrative Review and a Call to Action.Infectious diseases and therapy · 2026Review
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Integrated wet lab and in silico discovery and characterization of bacteriophages with antibiotic synergy against multidrug resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Bacteriophages as Antibacterial Agents Against Bovine Pathobionts Associated with Foodborne Human Morbidity.Viruses · 2026Review
- Imipenem-Induced Transcriptional Responses of Porin, Efflux Pumps, and Carbapenemase Genes in Clinical Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- Genomic landscape of completeFrontiers in microbiology · 2026Article
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy.Scientific reports · 2025Article
- Phage Therapy forAntibiotics (Basel, Switzerland) · 2025Review
- A Newly DiscoveredAntibiotics (Basel, Switzerland) · 2025Article
- Genomic and Functional Characterization of Novel Phages Targeting Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance in Acinetobacter baumannii poses a significant global health challenge. Phage therapy, particularly through phage-antibiotic synergy (PAS), offers a promising strategy to combat this pathogen. This study demonstrated significant PAS, where the combination of phage Indie and ceftazidime achieved a bacterial reduction of more than 85% of A. baumannii strain AbAK03 at 17 h using low doses. Notably, this combination overcame phage resistance observed at 4 h when the phage was used alone, extending bacterial eradication by 13 h. Furthermore, phage Indie restored bacterial susceptibility to ceftazidime, supporting its role in improving interventional treatments against multidrug-resistant A. baumannii. To explore this interaction, phage Indie was isolated and characterized from multidrug-resistant clinical strains. An in vitro PAS experiment was performed using ceftazidime and piperacillin-tazobactam. The combination of phage Indie with ceftazidime consistently showed superior bactericidal effects compared to either agent alone, while the combination of phage Indie with piperacillin-tazobactam exhibited an antagonistic effect. These findings provide clear evidence supporting the application of phage-antibiotic combinations as an effective intervention strategy and lay the groundwork for future in vivo trials in a mouse model to combat antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.